Brokerages Set Stoke Therapeutics, Inc. (NASDAQ:STOK) Price Target at $23.20

Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) has been given an average rating of "Buy" by the seven research firms that are currently covering the stock, Marketbeat reports. Five research analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $23.20.

A number of research firms have weighed in on STOK. Chardan Capital restated a "buy" rating and issued a $24.00 price target on shares of Stoke Therapeutics in a research note on Wednesday, March 19th. HC Wainwright dropped their price target on Stoke Therapeutics from $47.00 to $35.00 and set a "buy" rating for the company in a report on Wednesday, May 14th. Needham & Company LLC reaffirmed a "buy" rating and issued a $22.00 price objective on shares of Stoke Therapeutics in a report on Wednesday, April 9th. Finally, Cantor Fitzgerald upgraded Stoke Therapeutics to a "strong-buy" rating in a research note on Wednesday, May 14th.

Stoke Therapeutics Stock Performance

NASDAQ STOK traded down $0.06 during trading on Thursday, reaching $10.88. 372,305 shares of the company traded hands, compared to its average volume of 703,927. The company has a market cap of $594.02 million, a price-to-earnings ratio of -5.18 and a beta of 1.20. Stoke Therapeutics has a 1-year low of $5.35 and a 1-year high of $17.58. The stock's 50 day moving average price is $8.58 and its two-hundred day moving average price is $9.67.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last issued its earnings results on Monday, March 24th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.56) by $0.38. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. The company had revenue of $22.61 million during the quarter, compared to analysts' expectations of $4.20 million. Equities research analysts expect that Stoke Therapeutics will post -2.01 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Edward M. Md Kaye sold 10,382 shares of the business's stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total transaction of $90,011.94. Following the transaction, the director now owns 148,253 shares in the company, valued at $1,285,353.51. The trade was a 6.54% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Barry Ticho sold 3,884 shares of the business's stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total value of $33,674.28. Following the transaction, the insider now owns 63,962 shares in the company, valued at approximately $554,550.54. This represents a 5.72% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 24,748 shares of company stock worth $225,687. Corporate insiders own 11.30% of the company's stock.

Institutional Trading of Stoke Therapeutics

Large investors have recently bought and sold shares of the company. Toronto Dominion Bank purchased a new position in Stoke Therapeutics in the 4th quarter worth approximately $35,001,000. RTW Investments LP lifted its holdings in shares of Stoke Therapeutics by 10.1% in the 4th quarter. RTW Investments LP now owns 5,123,525 shares of the company's stock valued at $56,512,000 after acquiring an additional 471,240 shares during the last quarter. Checkpoint Capital L.P. lifted its holdings in shares of Stoke Therapeutics by 139.3% in the 1st quarter. Checkpoint Capital L.P. now owns 730,717 shares of the company's stock valued at $4,859,000 after acquiring an additional 425,330 shares during the last quarter. Erste Asset Management GmbH bought a new position in shares of Stoke Therapeutics in the 1st quarter valued at about $2,670,000. Finally, Jacobs Levy Equity Management Inc. bought a new stake in Stoke Therapeutics in the first quarter worth about $2,376,000.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.